FLAURA final analysis: osimertinib for first-line EGFRm NSCLC

Suresh Ramalingam: Osimertinib vs comparator EGFR-TKI 1st-line in EGFRm advanced NSCLC (FLAURA)Подробнее

Final overall survival (OS) data from FLAURA trialПодробнее

Osimertinib suitable for first line EGFRm lung cancerПодробнее

FLAURA Trial: Impact of OS Data in Advanced NSCLCПодробнее

New agents for EGFR+ NSCLC: osimertinib and beyondПодробнее

The FLAURA Trial: Practice-Changing Results for EGFR Mutation-Positive NSCLC (BMIC-007)Подробнее

Advanced-Stage NSCLC: Overall Survival Data from FLAURAПодробнее

FLAURA2: EGFRm dynamics in NSCLC treated with osimertinibПодробнее

FLAURA study of osimertinib versus TKI for 1st line NSCLCПодробнее

Dr. Hassan on FLAURA Trial Results in EGFR-Mutant NSCLCПодробнее

NSCLC: Integrating EGFR-Inhibiting Therapies into Clinical Pathways for First-Line TreatmentПодробнее

FLAURA study: a new standard of care for patients with EGFR mutated NSCLCПодробнее

First-line osimertinib in EGFR mutant aNSCLC patients: Progression pattern and safety in the rea...Подробнее

Early Returns on FLAURA Trial: Osimertinib as First Line Agent in EGFR Mut-Pos. NSCLC? (BMIC-002)Подробнее

ASCO 2023 Highlights on adjuvant osimertinib in resected EGFR mutated NSCLC: The ADAURA trialПодробнее

Overall-survival analysis of ADAURA: osimertinib in resected EGFRm stage IB-IIIA NSCLCПодробнее

Osimertinib and the FLAURA TrialПодробнее

Oleclumab plus osimertinib for advanced EGFRm NSCLCПодробнее

Front-line osimertinib significantly lengthens overall survival in EGFR-mutation positive NSCLCПодробнее